vs
Caesarstone Ltd.（CSTE）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Caesarstone Ltd.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.3倍（$94.4M vs $75.5M），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-47.1M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -57.8%）
凯撒斯通有限公司成立于1987年，总部位于以色列，是一家上市建材企业，主要生产销售石英、陶瓷、矿物及融合工艺饰面材料，产品广泛应用于厨房台面、化妆台面板、墙面装饰、室内地板及各类整体室内设计项目，目前在美国纳斯达克上市。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CSTE vs PBYI — 直观对比
营收规模更大
CSTE
是对方的1.3倍
$75.5M
自由现金流更多
PBYI
多$61.4M
$-47.1M
两年增速更快
PBYI
近两年复合增速
-57.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.4M | $75.5M |
| 净利润 | $-87.9M | — |
| 毛利率 | 15.5% | 69.3% |
| 营业利润率 | -87.2% | 22.7% |
| 净利率 | -93.1% | — |
| 营收同比 | — | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-2.55 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTEPBYI
| Q4 25 | $94.4M | $75.5M | ||
| Q3 25 | $345.4M | $54.5M | ||
| Q2 25 | $237.7M | $52.4M | ||
| Q1 25 | — | $46.0M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | $436.7M | $80.5M | ||
| Q2 24 | $294.3M | $47.1M | ||
| Q1 24 | $150.6M | $43.8M |
净利润CSTEPBYI
| Q4 25 | $-87.9M | — | ||
| Q3 25 | $-18.5M | $8.8M | ||
| Q2 25 | $-14.3M | $5.9M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-57.4M | $20.3M | ||
| Q2 24 | $-56.6M | $-4.5M | ||
| Q1 24 | $-3.9M | $-4.8M |
毛利率CSTEPBYI
| Q4 25 | 15.5% | 69.3% | ||
| Q3 25 | 22.5% | 77.7% | ||
| Q2 25 | 23.7% | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | 15.7% | 63.9% | ||
| Q2 24 | 14.1% | 77.4% | ||
| Q1 24 | 19.7% | 75.5% |
营业利润率CSTEPBYI
| Q4 25 | -87.2% | 22.7% | ||
| Q3 25 | -5.5% | 17.6% | ||
| Q2 25 | -6.2% | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | -12.6% | 27.4% | ||
| Q2 24 | -18.0% | -4.6% | ||
| Q1 24 | -3.9% | -5.3% |
净利率CSTEPBYI
| Q4 25 | -93.1% | — | ||
| Q3 25 | -5.4% | 16.2% | ||
| Q2 25 | -6.0% | 11.2% | ||
| Q1 25 | — | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -13.1% | 25.2% | ||
| Q2 24 | -19.2% | -9.6% | ||
| Q1 24 | -2.6% | -11.0% |
每股收益（稀释后）CSTEPBYI
| Q4 25 | $-2.55 | $0.26 | ||
| Q3 25 | $-0.54 | $0.17 | ||
| Q2 25 | $-0.41 | $0.12 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | $-1.67 | $0.41 | ||
| Q2 24 | $-1.64 | $-0.09 | ||
| Q1 24 | $-0.11 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.4M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $139.2M | $130.3M |
| 总资产 | $398.4M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CSTEPBYI
| Q4 25 | $58.4M | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | — | $107.2M |
总债务CSTEPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | $-12.6M | $102.0M |
股东权益CSTEPBYI
| Q4 25 | $139.2M | $130.3M | ||
| Q3 25 | $271.6M | $115.3M | ||
| Q2 25 | $271.6M | $104.7M | ||
| Q1 25 | — | $97.1M | ||
| Q4 24 | — | $92.1M | ||
| Q3 24 | $315.1M | $71.1M | ||
| Q2 24 | $315.1M | $48.5M | ||
| Q1 24 | $315.1M | $51.0M |
总资产CSTEPBYI
| Q4 25 | $398.4M | $216.3M | ||
| Q3 25 | $549.0M | $202.9M | ||
| Q2 25 | $549.0M | $194.9M | ||
| Q1 25 | — | $196.2M | ||
| Q4 24 | — | $213.3M | ||
| Q3 24 | $579.9M | $220.7M | ||
| Q2 24 | $579.9M | $205.0M | ||
| Q1 24 | $579.9M | $214.1M |
负债/权益比CSTEPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | -0.04× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-38.0M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.1M | $14.4M |
| 自由现金流率自由现金流/营收 | -49.8% | 19.1% |
| 资本支出强度资本支出/营收 | 9.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $38.6M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CSTEPBYI
| Q4 25 | $-38.0M | $14.4M | ||
| Q3 25 | $35.0M | $9.7M | ||
| Q2 25 | $18.7M | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $53.3M | $11.0M | ||
| Q2 24 | $25.1M | $1.0M | ||
| Q1 24 | $7.9M | $11.2M |
自由现金流CSTEPBYI
| Q4 25 | $-47.1M | $14.4M | ||
| Q3 25 | $26.7M | $9.7M | ||
| Q2 25 | $14.3M | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $44.6M | $11.0M | ||
| Q2 24 | $20.7M | $1.0M | ||
| Q1 24 | $5.0M | — |
自由现金流率CSTEPBYI
| Q4 25 | -49.8% | 19.1% | ||
| Q3 25 | 7.7% | 17.7% | ||
| Q2 25 | 6.0% | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | 10.2% | 13.7% | ||
| Q2 24 | 7.0% | 2.1% | ||
| Q1 24 | 3.3% | — |
资本支出强度CSTEPBYI
| Q4 25 | 9.6% | 0.0% | ||
| Q3 25 | 2.4% | 0.0% | ||
| Q2 25 | 1.8% | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 2.0% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 1.9% | 0.0% |
现金转化率CSTEPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTE
| America's | $53.0M | 56% |
| USA | $41.4M | 44% |
PBYI
暂无分部数据
